Emgality ® (galcanezumab-gnlm) injection

100 mg/mL, 120 mg/mL

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Is there an EMGALITY® (galcanezumab-gnlm) pregnancy registry?

An Emgality (galcanezumab) pregnancy registry is currently under review with the United States Food and Drug Administration.

Additional Information

A galcanezumab pregnancy registry is currently under review with the United States Food and Drug Administration. 

Pregnancy or related events can be reported to

  • the Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov/medwatch, or

  • Eli Lilly and Company at 1-800-LILLYRX (1-800-545-5979).

Enclosed Prescribing Information

EMGALITY® (galcanezumab-gnlm) injection, for subcutaneous use, Lilly

Date of Last Review: May 09, 2019

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 8am - 7pm ET

Or you can

Ask us a question Chat with us

Submit a Request

Visit Us @LillyMedical